A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

BACKGROUND: Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. METHODS: This phase 2, rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Laurence, McPhee, Roderick, Huang, Wenmei, Bennett, Hamilton, Pajon, Rolando, Nestorova, Biliana, Leav, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Moderna Therapeutics. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871769/
https://www.ncbi.nlm.nih.gov/pubmed/33707061
http://dx.doi.org/10.1016/j.vaccine.2021.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871769/
https://www.ncbi.nlm.nih.gov/pubmed/33707061
http://dx.doi.org/10.1016/j.vaccine.2021.02.007

Ejemplares similares